320 related articles for article (PubMed ID: 33927387)
21. A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex.
Avanzato VA; Oguntuyo KY; Escalera-Zamudio M; Gutierrez B; Golden M; Kosakovsky Pond SL; Pryce R; Walter TS; Seow J; Doores KJ; Pybus OG; Munster VJ; Lee B; Bowden TA
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25057-25067. PubMed ID: 31767754
[TBL] [Abstract][Full Text] [Related]
22. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
[TBL] [Abstract][Full Text] [Related]
23. Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.
Bradel-Tretheway BG; Liu Q; Stone JA; McInally S; Aguilar HC
J Virol; 2015 Jul; 89(14):7235-47. PubMed ID: 25948743
[TBL] [Abstract][Full Text] [Related]
24. Rhabdovirus-based vaccine platforms against henipaviruses.
Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
[TBL] [Abstract][Full Text] [Related]
25. Efficient reverse genetics reveals genetic determinants of budding and fusogenic differences between Nipah and Hendra viruses and enables real-time monitoring of viral spread in small animal models of henipavirus infection.
Yun T; Park A; Hill TE; Pernet O; Beaty SM; Juelich TL; Smith JK; Zhang L; Wang YE; Vigant F; Gao J; Wu P; Lee B; Freiberg AN
J Virol; 2015 Jan; 89(2):1242-53. PubMed ID: 25392218
[TBL] [Abstract][Full Text] [Related]
26. Architecture and antigenicity of the Nipah virus attachment glycoprotein.
Wang Z; Amaya M; Addetia A; Dang HV; Reggiano G; Yan L; Hickey AC; DiMaio F; Broder CC; Veesler D
Science; 2022 Mar; 375(6587):1373-1378. PubMed ID: 35239409
[TBL] [Abstract][Full Text] [Related]
27. Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.
Pickering BS; Hardham JM; Smith G; Weingartl ET; Dominowski PJ; Foss DL; Mwangi D; Broder CC; Roth JA; Weingartl HM
Vaccine; 2016 Sep; 34(40):4777-86. PubMed ID: 27544586
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein.
Byrne PO; Fisher BE; Ambrozak DR; Blade EG; Tsybovsky Y; Graham BS; McLellan JS; Loomis RJ
Nat Commun; 2023 Mar; 14(1):1494. PubMed ID: 36932063
[TBL] [Abstract][Full Text] [Related]
29. Type I interferon signaling protects mice from lethal henipavirus infection.
Dhondt KP; Mathieu C; Chalons M; Reynaud JM; Vallve A; Raoul H; Horvat B
J Infect Dis; 2013 Jan; 207(1):142-51. PubMed ID: 23089589
[TBL] [Abstract][Full Text] [Related]
30. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.
Kaku Y; Noguchi A; Marsh GA; McEachern JA; Okutani A; Hotta K; Bazartseren B; Fukushi S; Broder CC; Yamada A; Inoue S; Wang LF
J Virol Methods; 2009 Sep; 160(1-2):7-13. PubMed ID: 19433112
[TBL] [Abstract][Full Text] [Related]
31. Construction of the safe neutralizing assay system using pseudotyped Nipah virus and G protein-specific monoclonal antibody.
Bae SE; Kim SS; Moon ST; Cho YD; Lee H; Lee JY; Shin HY; Lee HJ; Kim YB
Biochem Biophys Res Commun; 2019 Jun; 513(4):781-786. PubMed ID: 30995971
[TBL] [Abstract][Full Text] [Related]
32. Indirect ELISA based on Hendra and Nipah virus proteins for the detection of henipavirus specific antibodies in pigs.
Fischer K; Diederich S; Smith G; Reiche S; Pinho Dos Reis V; Stroh E; Groschup MH; Weingartl HM; Balkema-Buschmann A
PLoS One; 2018; 13(4):e0194385. PubMed ID: 29708971
[TBL] [Abstract][Full Text] [Related]
33. A Recombinant Chimeric Cedar Virus-Based Surrogate Neutralization Assay Platform for Pathogenic Henipaviruses.
Amaya M; Yin R; Yan L; Borisevich V; Adhikari BN; Bennett A; Malagon F; Cer RZ; Bishop-Lilly KA; Dimitrov AS; Cross RW; Geisbert TW; Broder CC
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243163
[TBL] [Abstract][Full Text] [Related]
34. Hendra virus and Nipah virus animal vaccines.
Broder CC; Weir DL; Reid PA
Vaccine; 2016 Jun; 34(30):3525-34. PubMed ID: 27154393
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
Zeitlin L; Cross RW; Woolsey C; West BR; Borisevich V; Agans KN; Prasad AN; Deer DJ; Stuart L; McCavitt-Malvido M; Kim DH; Pettitt J; Crowe JE; Whaley KJ; Veesler D; Dimitrov A; Abelson DM; Geisbert TW; Broder CC
Sci Transl Med; 2024 Apr; 16(741):eadl2055. PubMed ID: 38569014
[TBL] [Abstract][Full Text] [Related]
36. Development of a neutralization assay for Nipah virus using pseudotype particles.
Tamin A; Harcourt BH; Lo MK; Roth JA; Wolf MC; Lee B; Weingartl H; Audonnet JC; Bellini WJ; Rota PA
J Virol Methods; 2009 Sep; 160(1-2):1-6. PubMed ID: 19559943
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of Hendra and Nipah virus infection in humans.
Escaffre O; Borisevich V; Rockx B
J Infect Dev Ctries; 2013 Apr; 7(4):308-11. PubMed ID: 23592639
[TBL] [Abstract][Full Text] [Related]
38. Animal Models for Henipavirus Research.
Pigeaud DD; Geisbert TW; Woolsey C
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896758
[TBL] [Abstract][Full Text] [Related]
39. A treatment for and vaccine against the deadly Hendra and Nipah viruses.
Broder CC; Xu K; Nikolov DB; Zhu Z; Dimitrov DS; Middleton D; Pallister J; Geisbert TW; Bossart KN; Wang LF
Antiviral Res; 2013 Oct; 100(1):8-13. PubMed ID: 23838047
[TBL] [Abstract][Full Text] [Related]
40. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.
Prabakaran P; Zhu Z; Xiao X; Biragyn A; Dimitrov AS; Broder CC; Dimitrov DS
Expert Opin Biol Ther; 2009 Mar; 9(3):355-68. PubMed ID: 19216624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
